All News
NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
Read Article
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
Read Article
Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d. (Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Dr. Robert Chao ( @doctorRBC ) reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented at the virtual EULAR 2021 meeting.
https://t.co/7FmZ4BzHwp
Links:
Dr. John Cush RheumNow ( View Tweet)
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
https://t.co/pMXWmuJw5Y https://t.co/1raYa1vLtK
Links:
Dr. John Cush RheumNow ( View Tweet)
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J
Links:
Dr. John Cush RheumNow ( View Tweet)
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download wherever you get your podcasts!
https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU
Links:
Dr. John Cush RheumNow ( View Tweet)
Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly https://t.co/LpEOgbcfpP
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3
Links:
Dr. John Cush RheumNow ( View Tweet)
Are You a High or Low Glucocorticoid Prescriber?
https://t.co/QbJzlrVMiV https://t.co/dZgJPKjisx
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Read more on #RheumNow
https://t.co/Q422Sl5Csj
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/2IvMIfPBkr
Links:
Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/1pnXJkoCOn
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it…
Still’s Disease Following COVID-19 Vaccination
Read more on #RheumNow
https://t.co/23R41Pydve https://t.co/a44cYIkc98
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hepatitis B Reactivation with Rituximab and Abatacept
A serologic study of rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without HBsAb positivity.
https://t.co/l1qCrWCyZd
#RheumNow https://t.co/EUoWt9xGdB
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it:
FDA Approves Avacopan for ANCA-Associated Vasculitis
https://t.co/L7UwhYBaVY
#RheumNow https://t.co/HypjLMLwjU
Links:
Dr. John Cush RheumNow ( View Tweet)